MedTrace Logo

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

NCT03265496 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-03-17

No results posted yet for this study

Summary

Condorde main objective is to evaluate the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed on ctDNA after liquid biopsy. EGFR status will be assessed by real time PCR (rtPCR), digital PCR (dPCR) and Next Generation Sequencing (NGS) in patients with chemotherapy naive lung carcinoma.

Conditions

Interventions

PROCEDURE

Clinical exam

Clinical exam is performed before treatment start

PROCEDURE

Liquid biopsy

Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease

PROCEDURE

Diagnostic exam

Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.

DRUG

1st line treatment

1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.

PROCEDURE

tumor evaluation

Tumor evaluation will be performed every 3 cycles of chemotherapy

BIOLOGICAL

Biopsy

Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.

Sponsors & Collaborators

  • University Hospital, Lille

    collaborator OTHER

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Kotecki Nuria, MD · Centre Oscar Lambret

  • Cortot Alexis, Pr · CHRU LILLE

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-07
Primary Completion
2021-04-13
Completion
2021-04-13

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03265496 on ClinicalTrials.gov